Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Exclusion Criteria

• •Non-plaque forms of psoriasis (e.g., guttate, erythrodermic or pustular)
• •Current drug-induced or aggravated psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium-channel blockers, or lithium carbonate)
• •History of any of a list of pre-defined cardiovascular diseases
• •History or known presence of any significant infectious, metabolic, oncological, ophthalmological or respiratory system disease or illness likely to render the subject unsuitable for the study.
• •Previous exposure to any other S1P receptor modulator
• •Receipt of a live vaccine within 28 days prior to randomisation
• •Need, or likely need for, treatment with Class I or III anti-arrhythmic drugs or with heart-rate-lowering beta-blockers or calcium-channel blockers, or with any other drugs which can reduce the heart rate
• •Clinically significant findings electrocardiogram (ECG) findings.